VUITY Only FDA-Approved Eye Drop to Treat Presbyopia is Now Available

Allergan, an AbbVie (NYSE: ABBV) company, today announced that VUITY (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the U.S. Food and Drug Administration (FDA) to treat presbyopia, is now available by prescription in pharmacies nationwide. Presbyopia, or age-related blurry near vision, can be diagnosed through a basic eye exam by an eye doctor (optometrist or ophthalmologist) and is a common and progressive eye condition that affects 128 million Americans, or nearly half of the U.S. adult population.


We are pleased to be able to bring this first-of-its-kind treatment to market sooner than expected for the millions of Americans with presbyopia who may benefit from it,” said Jag Dosanjh, senior vice president medical therapeutics, Allergan, an AbbVie company. “This significant innovation in age-related eye health reflects our commitment to advance vision care and expands our leading portfolio of treatments for eye care providers and their patients.”

Many Americans deal with presbyopia, which typically begins around age 40, by relying on reading glasses or resorting to work-arounds like zooming in on their digital devices to see up close. As an optometrist who also has presbyopia, I’m personally and professionally excited to try VUITY for myself, as well as offer it to my patients with age-related blurry near vision,” said optometrist Dr. Selina McGee, Fellow of the American Academy of Optometry. “With VUITY now available, it is a good time for those who experience age-related blurry near vision to visit their eye doctor for an exam and to discuss their options to manage this common condition.

Source: https://news.abbvie.com/

3D Printers to Produce Personalized Medicines

CurifyLabs and Natural Machines have entered a strategic partnership to develop a technology that enables customized medicine production through 3D printing – producing personalized medicines for human and veterinary patients, on-site in pharmacies and hospitals. Compounding is the manual preparation of individualized drug treatments for patients where an optimal treatment cannot be achieved with the currently available medicinal products. There are many talented pharmacists who are able to compound drugs manually but the process is ineffective and lacks quality control.

With this partnership, we are developing a unique Medicine-as-a-Service concept for pharmacy compounding and we believe that our partnership with Natural Machines will bring an affordable and superior 3D printing platform to the market. Together we can revolutionize the industry within personalized medicine offering localized, on-demand drug manufacturing.”, said Charlotta Topelius, CEO, CurifyLabs. This partnership aims to develop a unique solution that optimizes and automates the compounding process in pharmacies and hospitals, by utilizing 3D printers. CurifyLabs will commercialize the solution on a global scale. The two companies aim to introduce the technology to the market globally during 2022.

Our initial pilots have proved the potential to print personalized medicines based on CurifyLabs’ pharmaceutical formulations. We continue to focus on adapting the technology to establish a new approach for personalized medicine for our customers, based on pharma grade ingredients and integrated quality control”, said Niklas Sandler Topelius, Chief Scientific Officer, CurifyLabs.

Our partnership with CurifyLabs will help us to grow our portfolio. At Natural Machines, we have solutions for the food sector and the personal care industry, and now with this strategic partnership, we add the pharmaceutical field. This partnership will leverage both CurifyLabs’ experience and latest developments in pharma with our extensive 3D printing expertise, providing a new solution that aligns with the growing global trend of product personalization,” said Lynette Kucsma, founder and CMO of Natural Machines.

Source: https://www.3dprintingmedia.network/